A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive DisorderMontgomery S.A.a · Huusom A.K.T.b · Bothmer J.c
aImperial College School of Medicine, London, UK; bH. Lundbeck A/S, Copenhagen, Denmark; cLundbeck GmbH & Co., Hamburg, Germany Neuropsychobiology 2004;50:57–64 (DOI:10.1159/000078225)
This 8-week, randomised, double-blind study compared the efficacy and tolerability of escitalopram to that of venlafaxine XR in primary care patients with major depressive disorder. The efficacy of escitalopram (10– 20 mg; n = 148) was similar to venlafaxine XR (75– 150 mg; n = 145), based on mean change from baseline to week 8 in Montgomery and Åsberg Depression Rating Scale total score. In ad hoc analyses, escitalopram-treated patients achieved sustained remission significantly faster than did venlafaxine-treated patients. More venlafaxine-treated patients had nausea, constipation, and increased sweating (p < 0.05). When treatment was completed after 8 weeks, significantly more venlafaxine-treated patients had discontinuation symptoms (p < 0.01). Thus escitalopram treatment was similar to venlafaxine treatment with respect to efficacy and was better tolerated by patients in primary care.
|Direct payment||This item at the regular price: USD 38.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50